New Orleans – Novartis announced this morning that their novel pan-HDAC inhibitor, panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone significantly prolonged progression-free survival (PFS) of patients with Multiple Myeloma in the phase III PANORAMA-1 trial.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Posted by